Gone are the days when pharma companies could charge ... following in the footsteps of rival CRO, ICON plc, which acquired value strategy market access consultancy PriceSpective in early 2012.

ICON’s Pricing and Market Access team ... will have special focuses on disruptive technologies in pharma, R&D innovation, market access and commercialisation, oncology, sales & marketing ...

EZZ has served up a strong H2 FY25 result, with several financial and operational achievements throughout the quarter. ... Read More The post ASX Quarterly Health Wrap: EZZ hits an ace, ReNerve’s ...

As the pharmaceutical landscape evolves, ensuring market access should remain a top priority for industry stakeholders. As we look ahead to a year of expected advancements, several key trends will ...

IOI Corporation Berhad (IOI), through our German subsidiary KetoLipix Therapeutics GmbH (KetoLipix), is leading ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

Agreement drives continued patient access to four important therapies in Japan and KoreaStrengthens Essential Pharma and Clinigen’s combined ...

Beijing has announced new market access updates, signaling China’s significant opening ... telecommunications, and pharmaceutical R&D. The updates also reflect Beijing government’s broader strategy of ...

When you trade with a traditional brokerage account, you don’t actually access the stock market. Your order goes to your brokerage firm’s trading desk before it’s passed off to a market ...

Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Industry leaders anticipate that national standardization would simplify operations, expand market access and attract more ... RQS has aligned with a cultural icon to broaden its appeal.